FSD BioSciences is focused on advancing research and development of synthetic cannabinoids and compounds that target the endocannabinoid system.
Potential indication areas:
- Central Nervous System (CNS) disorders
- Chronic pain, including opioid-sparing
- Dermatological conditions
- Women’s health
- GI tract
Prismic Pharmaceuticals was acquired by FSD Pharma in June 2019. Prismic is a US-based specialty pharmaceutical company dedicated to developing novel non-addictive prescription drugs for the treatment of pain and inflammation.